A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1 Clinical Trial

Official title:

Pharmacodynamics of LY2963016 Compared to LANTUS® in Subjects With Type 1 Diabetes Mellitus

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01600950
• Other study ID #: 13831
• Secondary ID: I4L-MC-ABEE
• Status: Completed
• Phase: Phase 1
• First received: May 15, 2012
• Last updated: October 3, 2014
• Start date: May 2012
• Est. completion date: July 2012

Study information

• Verified date: October 2014
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationGermany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

The study involves a single injection of LY2963016 and a single injection of Lantus, on 2 separate occasions in participants with type I diabetes. Following each dose, participants will undergo a glucose clamp which lasts for 42 hours each time. There will be at least 7 days between the two periods, during which time there will be no study treatment, but participants will resume their regular therapy. The duration of this study can be up to 9.5 weeks. The purposes of this study are to understand how the blood sugar lowering effect of LY2963016 compares to that of Lantus, and to determine how LY2963016 and Lantus are metabolized by participants with type I diabetes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: July 2012
• Est. primary completion date: July 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• have type 1 diabetes mellitus (T1DM) based on the disease diagnostic criteria

• have had a duration of diabetes =1 year

• have hemoglobin A1c =10.0%

• have fasting C-peptide =0.3 nanomoles per liter (nmol/L)

• have a body mass index =29 kilograms per square meter (kg/m²)

• have venous access sufficient to allow blood sampling and cannulation for clamp procedures

Exclusion Criteria:

• are currently enrolled in, have completed, or discontinued within the last 30 days from, a clinical trial involving an investigational drug or device or off-label use of a drug or device

• have a total insulin requirement >1.2 units per kilogram per day (U/kg/day)

• have a history of proliferative retinopathy

• have known allergies to insulin glargine, insulin lispro, heparin, or related compounds

• have an electrocardiogram (ECG) reading considered outside the normal limits

• have an abnormal blood pressure

• have abnormal clinical laboratory tests

• have a history or presence of/significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs

• history of deep leg vein thrombosis or a frequent appearance of deep leg vein thrombosis in first-degree relatives

• show evidence of significant active neuropsychiatric disease

• regular use of known drugs of abuse and/or show positive findings on drug screening

• show evidence of human immunodeficiency virus (HIV) and/or positive human HIV antibodies

• show evidence of hepatitis C and/or positive hepatitis C antibody

• show evidence of hepatitis B and/or positive hepatitis B surface antigen

• are women with a positive pregnancy test or women who are lactating

• have an average weekly alcohol intake that exceeds 21 units per week (males) or 14 units per week (females)

• had more than 1 episode of severe hypoglycemia within 6 months prior to study

• undergoing therapy for a malignancy other than basal cell or squamous cell skin cancer

• had a blood transfusion or severe blood loss within 3 months; made a blood donation within 30 days prior to study entry; or have known hemoglobinopathy, haemolytic anemia, or sickle cell anemia

• are receiving systemic glucocorticoid therapy

• have irregular sleep/wake cycle (for example, participants who sleep during the day and work during the night)

• show a history of adverse reactions to heparin, including heparin-induced thrombocytopenia

• smoke more than 10 cigarettes (or equivalent other tobacco products) per day

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1

Intervention

Drug:
• LY2963016
Single 0.3 U/kg dose administered subcutaneously
• Lantus
Single 0.3 U/kg dose administered subcutaneously

Locations

Country	Name	City	State
Germany	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.	Neuss

Sponsors (1)

Lead Sponsor	Collaborator
Eli Lilly and Company

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacodynamics: Duration of Action of LY2963016 and Lantus	Duration of action is defined as the period of time elapsed between dose administration and the time at which the participant's blood glucose is consistently >150 milligrams/deciliter (mg/dL) without any glucose infusion. Participants whose blood glucose did not rise to 150 mg/dL were censored 42 hours postdose.	Periods 1 and 2: Baseline up to 42 hours postdose	No
Secondary	Maximum Glucose Infusion Rate (Rmax)	Rmax is the maximum infusion rate of glucose administered intravenously needed to maintain a target blood glucose level of 100 milligrams/deciliter (mg/dL) [5.6 millimoles/Liter (mmol/L)] and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of study drug by adjusting the exogenous glucose infusion rate. Data presented are the maximum infusion rates, adjusted by body weight.	Periods 1 and 2: Baseline up to 42 hours postdose	No
Secondary	Total Glucose Infused (Gtot)	Gtot is the total glucose infusion over the clamp duration and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of study drug by adjusting the exogenous glucose infusion rate. Data presented are the total glucose infused, adjusted by body weight.	Periods 1 and 2: Baseline up to 42 hours postdose	No
Secondary	Time of Maximum Glucose Infusion Rate (tRmax)	tRmax is the time to reach maximum glucose infusion rate and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of study drug by adjusting the exogenous glucose infusion rate.	Periods 1 and 2: Baseline up to 42 hours postdose	No
Secondary	Pharmacokinetics: Maximum Concentration (Cmax) of LY2963016 and Lantus	Cmax was not analyzed because of insufficient data due to concentrations being below the quantifiable lower limit of the assay.	Periods 1 and 2: Baseline up to 42 hours postdose	No
Secondary	Pharmacokinetics: Area Under the Concentration-time Curve (AUC) of LY2963016 and Lantus	AUC was not analyzed because of insufficient data due to concentrations being below the quantifiable lower limit of the assay.	Periods 1 and 2: Baseline up to 42 hours postdose	No